Consistent with this notion, treatment with the RIPK1 inhibitor, Nec-1s, or the MLKL inhibitor necrosulfonamide (NSA) reduced IMQ-induced psoriasis, with the caveats that NSA targets GSDMD rather than MLKL in mice, and the fact that a further study found no role genetically for the kinase activity of RIPK1 or RIPK3 [161,162]. This evidence concerns the gene RIPK3 and psoriasis.